Welcome to the Exeter Clinical Laboratory International website
NHS logo

Intravenous Immunoglobulins

Before requesting Intravenous Immunoglobulins (IVIg) refer to the Commissioning Guidance for the use of therapeutic immunoglobulin (Ig) in immunology, haematology, neurology and infectious diseases in England 2021 update. This describes the conditions which can be effectively treated with IVIgs.

For indications not covered by the above national guidance please contact the Transfusion Laboratory on ext. 2465 for advice

Requests for IVIg can only be obtained if an intravenous immunoglobulin registration form is completed by a Registrar or Consultant:

IVIg short term registration form

IVIg long term immunomodulatory registration form

IVIg long term replacement registration form

  • Once the request form is received, the completed requests are then approved or refused by the RD&E IVIg panel. A panel member can be contacted via the Transfusion Laboratory (ext 2467) during core hours or contact the Consultant Haematologist via switchboard out of hours.
  • To assist in calculating the required dose for patients the IVIg ideal body weight calculator should be used. The Dose/Kg field refers to the dose the patient will receive for that treatment episode (i.e. if the patient needs 0.4g/kg/day for 5 days the total they require is 2g/kg.)
  • Once approval for the supply of the IVIg has been granted. The Transfusion Laboratory needs to be informed of when the patient will require the product. To ensure that stocks of the product are sufficient to supply on the day.
  • Should supplies be insufficient, the Transfusion department will contact the Registrar or Consultant to discuss what alternative treatments/products can be offered.
  • Provided stocks are available  the IVIg is then issued on the day of the first dose of treatment.
  • Infusion rate information can be sen in the administration of IVIg form
  • Upon completion of the days infusion, the enclosed ‘Infusion form’ must be completed & returned to the Transfusion Laboratory.
  • Upon completion of one course of treatment, a follow up form (which is supplied with the last dose of a course of treatment) must be completed and returned to the Transfusion laboratory. Further courses of treatments can not start until these forms have been completed & sent back to the Transfusion Laboratory (A204).
  • Currently only enough IVIg is available for patients with Red or usually Blue indications in the ‘Immunoglobulin Guidelines and Demand Management Plan’.
University of Exeter logo
UKAS Medical logo


Royal Devon University Healthcare logo